Tonix Pharmaceuticals stock halted ahead of FDA approval news
Amrize Ltd (V8:AMRZ) President of Building Materials, Hill Jaime, reported purchasing 4,000 shares of Ordinary Shares on August 8, 2025. The shares were bought at a price of $46.4, totaling $185,600. The purchase appears well-timed, as the stock has gained over 10% in the past week, now trading at $51.83. Following the transaction, Hill Jaime directly owns 9,601 shares of Amrize Ltd, a company currently valued at $28.3 billion. According to InvestingPro data, analysts maintain a bullish outlook with price targets ranging from $49 to $64, and the company shows GOOD overall financial health. For deeper insights into Amrize’s valuation and growth prospects, InvestingPro offers additional analysis and metrics.
In other recent news, Amrize Ltd has been the focus of several analyst ratings and corporate developments. Bernstein SocGen Group reiterated its Outperform rating on Amrize, maintaining a $62 price target, while RBC Capital adjusted its price target from $61 to $54, citing guidance concerns. Despite the lowered target, RBC Capital still holds an Outperform rating, suggesting confidence in the stock’s potential. Meanwhile, JPMorgan initiated coverage with an Overweight rating and a $57 price target, emphasizing the company’s growth prospects.
In a strategic move, Amrize has partnered with Meta to develop an AI-optimized concrete mix for Meta’s data center in Rosemount, Minnesota. This innovative project aims to deliver high-strength concrete while reducing the carbon footprint by 35%, showcasing Amrize’s commitment to sustainable solutions. Additionally, Bernstein SocGen Group initiated coverage with an Outperform rating and a $62 price target, highlighting Amrize’s strong market position and pricing power. These recent developments underscore Amrize’s strategic initiatives and the varied analyst perspectives on its future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.